19741-14-1

Basic information

• Product Name: 4-[N-(2,4-DIAMINO-6-PTERIDINYLMETHYL)-N-METHYLAMINO] BENZOIC ACID
• Synonyms: 2,4-Diamino-N(10)-methylpteroic acid;4-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoic acid;Deoxyaminopteroic acid;N-10-Methyl-4-deoxy-4-aminopteroate;Nsc 131463;DAMPA;4-[N-[(2,4-DiaMinopyriMido[4,5-b]pyrazin-6-yl)Methyl]-N- MethylaMino]benzoic Acid;4-AMino-4-deoxy-10-Methylpteroic Acid
• CAS NO: 19741-14-1
• Molecular Formula: C₁₅H₁₅N₇O₂
• Molecular Weight: 325.33
• Product Categories: Bases & Related Reagents;Drug Analogues;Heterocycles;Intermediates & Fine Chemicals;Nucleotides;Pharmaceuticals
• Mol File: 19741-14-1.mol
• Article Data: 21

Chemical Properties

• Melting Point: 255 °C (dec.)(lit.)
• Boiling Point: 689.3 °C at 760 mmHg
• Flash Point: 370.7 °C
• Appearance: /
• Density: 1.532
• Vapor Pressure: 5.96E-20mmHg at 25°C
• Refractive Index: 1.799
• Storage Temp.: 2-8°C(protect from light)
• Solubility: Aqueous Base, DMSO
• PKA: 4.63±0.10(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: 4-[N-(2,4-DIAMINO-6-PTERIDINYLMETHYL)-N-METHYLAMINO] BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[N-(2,4-DIAMINO-6-PTERIDINYLMETHYL)-N-METHYLAMINO] BENZOIC ACID(19741-14-1)
• EPA Substance Registry System: 4-[N-(2,4-DIAMINO-6-PTERIDINYLMETHYL)-N-METHYLAMINO] BENZOIC ACID(19741-14-1)

Safety Data

• Hazard Codes: Xi
• Statements: 43-52/53
• Safety Statements: 36/37
• WGK Germany: 3
• Hazardous Substances Data: 19741-14-1(Hazardous Substances Data)

Usage

Chemical Properties

Brownish Yellow to Orange Solid

Uses

Different sources of media describe the Uses of 19741-14-1 differently. You can refer to the following data:
1. DAMPA is a Methotrexate (M260675) analog (1). DAMPA is an antitumor agent (2).
2. DAMPA is a Methotrexate (M260675) analog

InChI:InChI=1/C15H15N7O2/c1-22(10-4-2-8(3-5-10)14(23)24)7-9-6-18-13-11(19-9)12(16)20-15(17)21-13/h2-6H,7H2,1H3,(H,23,24)(H4,16,17,18,20,21)

Upstream product

• 1004-74-6 2,4,5,6-tetraaminopyrimidine 
• 3475-39-6 1,1,3-tribromoacetone 
• 10541-83-0 N-methyl-p-aminobenzoic acid 
• 945-24-4 2,4-diamino-6-(hydroxymethyl)pteridine 
• 7532-09-4 methotrexate sodium salt 
• 23853-09-0 4-[(2,4-diaminopteridin-6-ylmethyl)-N-methylamino]benzoic acid methyl ester 
• 59368-16-0 6-bromomethyl-pteridine-2,4-diamine 
• 18358-63-9 methyl 4-(N-methyl)aminobenzoate 
• 127-19-5 N,N-dimethyl acetamide 
• 150-13-0 4-amino-benzoic acid 
• 73978-41-3 2,4-diamino-6-(hydroxymethyl)pteridine hydrochloride 
• 52853-40-4 6-bromomethyl-2,4-diaminopteridine hydrobromide 
• 5221-17-0 2,3-dibromopropanal 
• 59-05-2 N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid 

Downstream Products

• 5623-18-7 10-methyl-pteroic acid 
• 56892-83-2 4-{4-[(2,4-diamino-pteridin-6-ylmethyl)-methyl-amino]-benzoyl}-morpholine 
• 112113-88-9 3-10methylpteroyl)-N-(carboxymethyl)amino>propanoic acid bis(ethyl ester) 
• 67022-39-3 γ-methyl N'-<4--N-methylamino>benzoyl>-L-glutamate 
• 82972-54-1 4-amino-4-deoxy-N¹⁰-methylpteroyl-(6-diazo-5-oxo)-L-norleucine 
• 113811-46-4 N-(4-amino-4-deoxy-N¹⁰-methylpteroyl)-2-aminoethanesulfonic acid 
• 113811-47-5 N-(4-amino-4-deoxy-N¹⁰-methylpteroyl)-3-aminopropanesulfonic acid 
• 113811-48-6 N-(4-amino-4-deoxy-N¹⁰-methylpteroyl)-4-aminobutanesulfonic acid 
• 113811-49-7 N-(4-amino-4-deoxy-N¹⁰-methylpteroyl)-2-aminoethanephosphonic acid 
• 79640-68-9 α-methyl γ-tert-butyl N-(4-amino-4-deoxy-N¹⁰-methylpteroyl)-L-glutamate 
• 95485-10-2 (S)-2-{4-[(4-Amino-2-formimidoylamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid 5-tert-butyl ester 1-methyl ester 
• 95485-11-3 (S)-2-{4-[(2-Amino-4-formimidoylamino-pteridin-6-ylmethyl)-methyl-amino]-benzoylamino}-pentanedioic acid 5-tert-butyl ester 1-methyl ester 
• 113811-45-3 [N-(4-amino-4-deoxy-N¹⁰-methylpteroyl)amino]methanesulfonic acid 
• 95485-01-1 p-nitrophenyl 4-amino-4-deoxy-N¹⁰-formylpteroate 

Relevant articles and documents

Methotrexate prodrugs sensitive to reactive oxygen species for the improved treatment of rheumatoid arthritis

Methotrexate (MTX) is the standard of care in the treatment of rheumatoid arthritis (RA), a common autoimmune disease that is characterized by chronic inflammation in the synovial membrane of joints. Unfortunately, MTX suffers from high discontinuation ra

ANTIFOLATE-CARRYING NANOPARTICLES AND THEIR USE IN MEDICINE

The present invention provides a nanoparticle comprising: a core comprising a metal and/or a semiconductor; and a plurality of ligands covalently linked to the core, wherein said ligands comprise: (i) at least one dilution ligand comprising a carbohydrate, glutathione or an ethylene glycol-containing moiety; and (ii) a ligand of the formula D-L1-Z-L2, wherein D comprises an antifolate drug or folic acid, L1 comprises a first linker portion comprising a C2-C12 glycol and/or C2-C12 alkyl chain, L2 comprises a second linker portion comprising a C2-C12 glycol and/or C2-C12 alkyl chain, wherein L1 and L2 may be the same or different, and wherein Z represents a carbonyl-containing group linking L1 and L2, and wherein L2 is coupled to said core, Also provided are pharmaceutical compositions comprising such nanoparticles, medical uses thereof and methods for producing the nanoparticles.

PRODRUGS ACTIVATED BY REACTIVE OXYGEN SPECIES FOR USE IN THE TREATMENT OF INFLAMMATORY DISEASES AND CANCER

Prodrugs activated predominantly or exclusively in inflammatory tissue, more particularly prodrugs of methotrexate and derivatives thereof, which are selectively activated by Reactive Oxygen Species (ROS) in inflammatory tissues associated with cancer and inflammatory diseases, as well as method for preparing said prodrugs.